Artificial intelligence-based volumetric measurements for longitudinal clinical assessment of treatment response in high-grade gliomas: Validation across institutional and public datasets
Open Access
- 12 January 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdag045
Abstract
High-grade gliomas (HGGs) require ongoing imaging to guide treatment, traditionally relying on labor-intensive and variable manual MRI measurements. While FDA-cleared artificial intelligence (AI) tools offer automated tumor volume segmentation, their clinical utility in decision-making remains understudied. This study assesses the utility and limitations of an FDA-cleared AI-based tool across public and institutional datasets, comparing its output with multidisciplinary tumor board (MDTB) assessments. We applied the FDA-cleared, AI-based tool Neosoma HGG to quantify tumor volumes in 214 subjects from public datasets and 49 from an institutional cohort. AI-derived volumes were compared to expert manual and other AI-based measurements. Therapeutic response assessments using RANO criteria were evaluated against MDTB diagnoses. Segmentation times were analyzed using mixed-model regression. We analyzed 1648 MRI sequences of 95 HGG patients across three datasets. Contrast-enhancing (CE) tumor volumes were consistent across AI platforms, and Neosoma HGG significantly reduced segmentation time (pre-operative: 210.5s, post-operative: 179s vs. 15 s, P < .0001). AI-informed disease state assessments showed an overall moderate agreement with MDTB diagnoses for progressive disease (k = 0.45, P < .00001). Key discrepancies arose from limitation of Neosoma HGG in distinguishing pseudo-progression from tumor progression. T2-FLAIR-derived volumes varied significantly between AI platforms (P < .001), with discordances largely due to over-segmentation beyond the tumor region. AI-based volumetric segmentation has the potential to improve efficiency and standardization in monitoring HGG, especially for CE tumor burden. However, moderate concordance with MDTB assessments and difficulties with FLAIR imaging underscore its current limitations. AI should serve as a clinical decision support tool, with further refinement needed to improve specificity and integrate multimodal imaging data.Keywords
This publication has 36 references indexed in Scilit:
- Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRIAmerican Journal of Neuroradiology, 2015
- Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trialsNeuro-Oncology, 2015
- Volumetric glioma quantification: comparison of manual and semi-automatic tumor segmentation for the quantification of tumor growthActa Radiologica, 2014
- Impact of imaging measurements on response assessment in glioblastoma clinical trialsNeuro-Oncology, 2014
- Glioblastoma and Other Malignant GliomasJAMA, 2013
- Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudyNeuro-Oncology, 2013
- Pseudoprogression in Patients With Glioblastoma Multiforme After Concurrent Radiotherapy and TemozolomideAmerican Journal of Clinical Oncology, 2012
- Interrater reliability: the kappa statisticBiochemia Medica, 2012
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005